The National Asthma Council Logo

 

 

Leading the attack against asthma

Search website
Home About the NAC Strategy Managing Asthma Research Emergency
 
Asthma Information Papers
 
Asthma Management Handbook Asthma Action Plans Spirometry Resources  Other Resources Information Papers Special Topics Professional Development  

Leukotriene receptor antagonists: their therapeutic role in children with asthma

Home
Key Points
Introduction
Diagnostic considerations in young children
Rationale for leukotriene antagonism in childhood asthma
Clinical evidence for montelukast use in children
Preventive treatment in children
Other potential roles of LTRAs
Acknowledgements
References
Appendices
Content created June 2007
Page updated June 2007

Get Acrobat Viewer

Leukotriene receptor antagonists: their therapeutic role in children with asthma

 

Contents

Key Points

Introduction

Diagnostic considerations in young children

Rationale for leukotriene antagonism in childhood asthma

Clinical evidence for montelukast use in children

Preventive treatment in children

Other potential roles of LTRAs

Acknowledgements

References

ForwardBack

Leukotriene receptor antagonists: their therapeutic role in children with asthma

Publication

Published by National Asthma Council Australia Ltd.
ACN 058 044 634
1 Palmerston Crescent
South Melbourne VIC 3205
Australia
Tel: (+61) 3 8699 0476    Email: nac@nationalasthma.org.au
Fax: (+61) 3 8699 0400    Website: www.nationalasthma.org.au

Copyright
© 2007 National Asthma Council Australia Ltd

Disclaimer

Although all care has been taken, this information paper is a general guide only, which is not intended to be a substitute for individual medical advice/treatment. The National Asthma Council Australia expressly disclaims all responsibility (including for negligence) for any loss, damage or personal injury resulting from reliance on the information contained herein.

Suggested citation:

National Asthma Council Australia. Leukotriene receptor antagonists: their therapeutic role in children with asthma. Revised June 2007. Melbourne: National Asthma Council Australia, 2007.

Proudly supported by Merck Sharp & Dohme

This information paper was supported by an unrestricted educational grant from Merck Sharp & Dohme (Australia) Pty Ltd. National Asthma Council Australia retained editorial control.

Top of page